Literature DB >> 8613855

Effects of prednisone on ventriculoperitoneal shunt function in hydrocephalus secondary to cysticercosis: a preliminary study.

R A Suastegui Roman1, J L Soto-Hernandez, J Sotelo.   

Abstract

In a prospective open study, 15 patients with hydrocephalus secondary to cysticercosis who required insertion of a ventriculoperitoneal (VP) shunt were treated with 50 mg of prednisone given orally three times a week. Treatment began in the 1st postoperative week, with isoniazid and pyridoxine administered daily as antituberculous chemoprophylaxis. The drug regimen was continued with close follow up for 24 months. Clinical status, Karnofsky performance status (KPS) scores, and postoperative course in the prednisone-treated group were compared with 30 control patients with hydrocephalus due to cysticercosis. The control patients were matched by age and sex, underwent surgical shunting in the same period, and were followed routinely by the neurosurgery staff. Lumbar cerebrospinal fluid (CSF) was studied in 2, 16, and 32 weeks postoperatively in the prednisone group. At 24-month follow up two (13%) of 15 patients in the prednisone group and 19 (60%) of 30 patients in the control group required surgical shunt revisions for symptomatic shunt obstruction (p=0.002). Follow-up studies of CSF performed at 32 weeks in the prednisone group revealed improvement of abnormal values with statistically significant differences for glucose (p<0.02). Serial imaging studies in the prednisone group revealed persistence of cysticercal cysts with no change in size. Mean initial KPS scores were similar in both groups. At the end of the follow-up period, the mean KPS score was significantly higher in the prednisone group (p=0.003). Prednisone and chemoprophylactic drugs were well tolerated. These results suggest that in selected patients with hydrocephalus secondary to cysticercosis, intermittent long-term prednisone therapy after VP shunting may reduce shunt malfunction and improve the functional status of the patients.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8613855     DOI: 10.3171/jns.1996.84.4.0629

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  15 in total

Review 1.  Clinical symptoms, diagnosis, and treatment of neurocysticercosis.

Authors:  Hector H Garcia; Theodore E Nash; Oscar H Del Brutto
Journal:  Lancet Neurol       Date:  2014-11-10       Impact factor: 44.182

2.  Neurocysticercosis: the effectiveness of the cysticidal treatment could be influenced by the host immunity.

Authors:  Graciela Cárdenas; Gladis Fragoso; Marcos Rosetti; Laura Uribe-Figueroa; Claudia Rangel-Escareño; Brenda Saenz; Marisela Hernández; Edda Sciutto; Agnes Fleury
Journal:  Med Microbiol Immunol       Date:  2014-06-24       Impact factor: 3.402

3.  Neurocysticercosis.

Authors:  Vincent C Marconi; Hector H Garcia; Joel T Katz
Journal:  Curr Infect Dis Rep       Date:  2006-06       Impact factor: 3.725

Review 4.  Hydrocephalus in neurocysticercosis.

Authors:  Hamilton Matushita; Fernando Campos Gomes Pinto; Daniel Dante Cardeal; Manoel Jacobsen Teixeira
Journal:  Childs Nerv Syst       Date:  2011-09-17       Impact factor: 1.475

Review 5.  Cysticercosis of the central nervous system: how should it be managed?

Authors:  Hector H Garcia; Armando E Gonzalez; Robert H Gilman
Journal:  Curr Opin Infect Dis       Date:  2011-10       Impact factor: 4.915

6.  Transient hemifacial spasm associated with subarachnoid brainstem cysticercosis: a case report.

Authors:  R Revuelta Gutierrez; J L Soto-Hernández; R Suastegui-Roman; J Ramos-Peek
Journal:  Neurosurg Rev       Date:  1998       Impact factor: 3.042

Review 7.  Pharmacokinetic optimisation of the treatment of neurocysticercosis.

Authors:  J Sotelo; H Jung
Journal:  Clin Pharmacokinet       Date:  1998-06       Impact factor: 6.447

Review 8.  Current consensus guidelines for treatment of neurocysticercosis.

Authors:  Hector H García; Carlton A W Evans; Theodore E Nash; Osvaldo M Takayanagui; A Clinton White; David Botero; Vedantam Rajshekhar; Victor C W Tsang; Peter M Schantz; James C Allan; Ana Flisser; Dolores Correa; Elsa Sarti; Jon S Friedland; S Manuel Martinez; Armando E Gonzalez; Robert H Gilman; Oscar H Del Brutto
Journal:  Clin Microbiol Rev       Date:  2002-10       Impact factor: 26.132

9.  Diagnosis and Treatment of Neurocysticercosis: 2017 Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH).

Authors:  A Clinton White; Christina M Coyle; Vedantam Rajshekhar; Gagandeep Singh; W Allen Hauser; Aaron Mohanty; Hector H Garcia; Theodore E Nash
Journal:  Clin Infect Dis       Date:  2018-04-03       Impact factor: 9.079

10.  Recent Developments in the Epidemiology, Diagnosis, Treatment, and Prevention of Neurocysticercosis.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-12       Impact factor: 3.663

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.